Chembio Diagnostics, Inc. (CEMI.OB) Enters Into Six-Month $480,000 Follow-On Contract With Centers for Disease Control and Prevention (CDC) Contractor for Point-of-Care Influenza Test Development  
7/17/2012 9:23:02 AM

MEDFORD, N.Y., July 17, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a NY-based company that develops, manufactures, licenses and markets proprietary rapid diagnostic tests, entered into a follow-on, milestone-based development agreement of up to $480,000 based on Chembio's previous successful initial development of a multiplex rapid point-of-care ("POC") influenza immunity test utilizing its patented Dual Path Platform (DPP®) technology. The agreement contemplates a period of approximately six months in which the follow-on development activity is to be completed.